NMR structure of a complex between MDM2 and a small molecule inhibitor
- PMID: 15557803
- DOI: 10.1023/B:JNMR.0000048856.84603.9b
NMR structure of a complex between MDM2 and a small molecule inhibitor
Abstract
MDM2 is a regulator of cell growth processes that acts by binding to the tumor suppressor protein p53 and ultimately restraining its activity. While inactivation of p53 by mutation is commonly observed in human cancers, a substantial percentage of tumors express wild type p53. In many of these cases, MDM2 is overexpressed, and it is believed that suppression of MDM2 activity could yield therapeutic benefits. Therefore, we have been focusing on the p53-MDM2 interaction as the basis of a drug discovery program and have been able to develop a series of small molecule inhibitors. We herein report a high resolution NMR structure of a complex between the p53-binding domain of MDM2 and one of these inhibitors. The form of MDM2 utilized was an engineered hybrid between the human and Xenopus sequences, which provided a favorable combination of relevancy and stability. The inhibitor is found to bind in the same site as does a highly potent peptide fragment of p53. The inhibitor is able to successfully mimic the peptide by duplicating interactions in three subpockets normally made by amino acid sidechains, and by utilizing a scaffold that presents substituents with rigidity and spatial orientation comparable to that provided by the alpha helical backbone of the peptide. The structure also suggests opportunities for modifying the inhibitor to increase its potency.
Similar articles
-
Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft.J Am Chem Soc. 2008 May 21;130(20):6472-8. doi: 10.1021/ja800201j. Epub 2008 Apr 25. J Am Chem Soc. 2008. PMID: 18435534
-
Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery.Cell Cycle. 2010 Mar 15;9(6):1104-11. doi: 10.4161/cc.9.6.10956. Epub 2010 Mar 15. Cell Cycle. 2010. PMID: 20237429
-
Over-expression of the human MDM2 p53 binding domain by fusion to a p53 transactivation peptide.Protein Expr Purif. 2004 Oct;37(2):493-8. doi: 10.1016/j.pep.2004.06.036. Protein Expr Purif. 2004. PMID: 15358376
-
Inhibitors of MDM2 and MDMX: a structural perspective.Future Med Chem. 2009 Sep;1(6):1075-94. doi: 10.4155/fmc.09.75. Future Med Chem. 2009. PMID: 21425995 Review.
-
Small-molecule inhibitors of the p53-MDM2 interaction.Curr Top Microbiol Immunol. 2011;348:151-72. doi: 10.1007/82_2010_110. Curr Top Microbiol Immunol. 2011. PMID: 21046355 Review.
Cited by
-
Ligand binding mode prediction by docking: mdm2/mdmx inhibitors as a case study.J Chem Inf Model. 2014 Feb 24;54(2):648-59. doi: 10.1021/ci4004656. Epub 2014 Jan 21. J Chem Inf Model. 2014. PMID: 24358984 Free PMC article.
-
Targeting protein-protein interactions for cancer therapy.J Mol Med (Berl). 2005 Dec;83(12):955-63. doi: 10.1007/s00109-005-0705-x. Epub 2005 Nov 11. J Mol Med (Berl). 2005. PMID: 16283145 Review.
-
Synthesis and Biological Evaluation of Novel Synthetic Indolone Derivatives as Anti-Tumor Agents Targeting p53-MDM2 and p53-MDMX.Molecules. 2022 Jun 9;27(12):3721. doi: 10.3390/molecules27123721. Molecules. 2022. PMID: 35744849 Free PMC article.
-
Benzimidazole-2-one: a novel anchoring principle for antagonizing p53-Mdm2.Bioorg Med Chem. 2013 Jul 15;21(14):3982-95. doi: 10.1016/j.bmc.2012.06.020. Epub 2012 Jun 20. Bioorg Med Chem. 2013. PMID: 22789708 Free PMC article.
-
Chemistry and biology of multicomponent reactions.Chem Rev. 2012 Jun 13;112(6):3083-135. doi: 10.1021/cr100233r. Epub 2012 Mar 22. Chem Rev. 2012. PMID: 22435608 Free PMC article. Review. No abstract available.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous